{"id":48089,"date":"2020-01-30T22:19:17","date_gmt":"2020-01-30T11:19:17","guid":{"rendered":"https:\/\/riskinfo.com.au\/news\/?p=48089"},"modified":"2020-02-05T21:30:31","modified_gmt":"2020-02-05T10:30:31","slug":"clearview-to-cease-agreed-value-ip-in-line-with-apra-timeframe","status":"publish","type":"post","link":"https:\/\/riskinfo.com.au\/news\/2020\/01\/30\/clearview-to-cease-agreed-value-ip-in-line-with-apra-timeframe\/","title":{"rendered":"ClearView to Cease Agreed Value IP in Line With APRA Timeframe"},"content":{"rendered":"<div class=\"co8aDb gsrt\" role=\"heading\" aria-level=\"3\">\n<p>ClearView Wealth has announced it will discontinue the sale of Agreed Value income protection insurance contracts from 31 March 2020.<\/p>\n<p>The insurer made this announcement in an <a href=\"https:\/\/www.asx.com.au\/asxpdf\/20200129\/pdf\/44dl3tg6wk0h56.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">ASX trading update<\/a>, in which it states it has already commenced a comprehensive review of its <a href=\"https:\/\/www.clearview.com.au\/LifeSolutions\" target=\"_blank\" rel=\"noopener noreferrer\">LifeSolutions IP<\/a> product series with a focus on reviewing product pricing and design.<\/p>\n<p>The company says this move stems from APRA\u2019s recent policy measures and the continued under-performance of the IP Portfolio. It notes it welcomes APRA&#8217;s intervention, which included a stated expectation from the regulator that all life companies will cease offering Agreed Value IP business from 31 March 2020 (see: <a href=\"https:\/\/riskinfo.com.au\/news\/2019\/12\/03\/apra-demands-new-course-for-ip-sustainability\/\" target=\"_blank\" rel=\"noopener noreferrer\">APRA Sets New Course&#8230;<\/a>).<\/p>\n<blockquote><p>ClearView &#8230;will launch a new indemnity type IP product later this year<\/p><\/blockquote>\n<p>In addition to ceasing Agreed Value IP from the end of March, ClearView also stated it will launch a new indemnity type IP product later this year, which is intended to offer a lower maximum monthly benefit at a competitive premium rate.<\/p>\n<p>The insurer noted it is highly likely that further price changes will be made in the coming months to reflect increased claim rates, and that the repricing of the product and a detailed review of its claims assumptions is also underway, leading it to state:<\/p>\n<p>\u201cAny further increases to the claims assumptions are intended to be recovered through premium rate increases&#8230;&#8221;<\/p>\n<blockquote><p>Some insurers appear to be engaging in \u2018honeymoon\u2019 discounting to maintain market share&#8230;<\/p><\/blockquote>\n<p>The insurer also took aim at new business discount offers, noting in its update that: \u201cSome insurers appear to be engaging in \u2018honeymoon\u2019 discounting to maintain market share rather than focusing on delivering long-term sustainable products and transparent pricing to customers.&#8221;<\/p>\n<\/div>\n<div class=\"co8aDb gsrt\" role=\"heading\" aria-level=\"3\">While it conceded its current new business volumes were being impacted by these discount offers, ClearView stated it is not participating in this approach, noting instead:<\/div>\n<div role=\"heading\" aria-level=\"3\"><\/div>\n<div class=\"co8aDb gsrt\" role=\"heading\" aria-level=\"3\">\u201cClearView\u2019s focus remains on lifting business quality, continuing to review our pricing profile, addressing the fundamental issues with income protection (IP) products offered in the market and meeting the needs of our customers.\u201d<\/div>\n<div role=\"heading\" aria-level=\"3\"><\/div>\n<div role=\"heading\" aria-level=\"3\">The insurer noted a further update on these initiatives will be provided in due course.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>ClearView Wealth has announced it will discontinue the sale of Agreed Value income protection insurance contracts from 31 March 2020. The insurer made this announcement in an ASX trading update, in which it states it has already commenced a comprehensive review of its LifeSolutions IP product series with a focus on reviewing product pricing and [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":48111,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[307,4247,8251],"class_list":["post-48089","post","type-post","status-publish","format-standard","has-post-thumbnail","category-products","tag-clearview","tag-feature","tag-ip-product"],"_links":{"self":[{"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/posts\/48089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/comments?post=48089"}],"version-history":[{"count":0,"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/posts\/48089\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/media\/48111"}],"wp:attachment":[{"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/media?parent=48089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/categories?post=48089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/riskinfo.com.au\/news\/wp-json\/wp\/v2\/tags?post=48089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}